Works matching AU Kyung Ah Han

Results: 50
    1
    2
    3
    4
    5
    6
    7
    8
    9
    10
    11
    12
    13
    14
    15
    16
    17
    18
    19
    20
    21
    22
    23
    24

    Efficacy and Safety of Evogliptin Add-on Therapy to Dapagliflozin/Metformin Combinations in Patients with Poorly Controlled Type 2 Diabetes Mellitus: A 24-Week Multicenter Randomized Placebo-Controlled Parallel-Design Phase-3 Trial with a 28-Week Extension

    Published in:
    Diabetes & Metabolism Journal, 2023, v. 47, n. 6, p. 808, doi. 10.4093/dmj.2022.0387
    By:
    • Jun Sung Moon;
    • Il Rae Park;
    • Hae Jin Kim;
    • Choon Hee Chung;
    • Kyu Chang Won;
    • Kyung Ah Han;
    • Cheol-Young Park;
    • Jong Chul Won;
    • Dong Jun Kim;
    • Gwan Pyo Koh;
    • Eun Sook Kim;
    • Jae Myung Yu;
    • Eun-Gyoung Hong;
    • Chang Beom Lee;
    • Kun-Ho Yoon
    Publication type:
    Article
    25
    26
    27

    Efficacy and Safety of Omega-3 Fatty Acids in Patients Treated with Statins for Residual Hypertriglyceridemia: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.

    Published in:
    Diabetes & Metabolism Journal, 2020, v. 44, n. 1, p. 78, doi. 10.4093/dmj.2018.0265
    By:
    • Ji Eun Jun;
    • In-Kyung Jeong;
    • Jae Myung Yu;
    • Sung Rae Kim;
    • In Kye Lee;
    • Kyung-Ah Han;
    • Sung Hee Choi;
    • Soo-Kyung Kim;
    • Hyeong Kyu Park;
    • Ji-Oh Mok;
    • Yong-ho Lee;
    • Hyuk-Sang Kwon;
    • So Hun Kim;
    • Ho-Cheol Kang;
    • Sang Ah Lee;
    • Chang Beom Lee;
    • Kyung Mook Choi;
    • Sung-Ho Her;
    • Won Yong Shin;
    • Mi-Seung Shin
    Publication type:
    Article
    28
    29
    30
    31
    32
    33
    34
    35
    36

    Efficacy and safety of enavogliflozin, a novel SGLT2 inhibitor, in Korean people with type 2 diabetes: A 24‐week, multicentre, randomized, double‐blind, placebo‐controlled, phase III trial.

    Published in:
    Diabetes, Obesity & Metabolism, 2023, v. 25, n. 7, p. 1865, doi. 10.1111/dom.15046
    By:
    • Kwak, Soo Heon;
    • Han, Kyung Ah;
    • Kim, Kyung‐Soo;
    • Yu, Jae Myung;
    • Kim, EunSook;
    • Won, Jong Chul;
    • Kang, Jun Goo;
    • Chung, Choon Hee;
    • Oh, Seungjoon;
    • Choi, Sung Hee;
    • Won, Kyu Chang;
    • Kim, Sin Gon;
    • Cho, Seung Ah;
    • Cho, Bo Young;
    • Park, Kyong Soo
    Publication type:
    Article
    37

    Efficacy and safety of ipragliflozin as an add‐on therapy to sitagliptin and metformin in Korean patients with inadequately controlled type 2 diabetes mellitus: A randomized controlled trial.

    Published in:
    Diabetes, Obesity & Metabolism, 2018, v. 20, n. 10, p. 2408, doi. 10.1111/dom.13394
    By:
    • Han, Kyung‐ah;
    • Chon, Suk;
    • Chung, Choon Hee;
    • Lim, Soo;
    • Lee, Kwan‐woo;
    • Baik, Seihyun;
    • Jung, Chang Hee;
    • Kim, Dong‐sun;
    • Park, Kyong Soo;
    • Yoon, Kun‐ho;
    • Lee, In‐kyu;
    • Cha, Bong‐soo;
    • Sakatani, Taishi;
    • Park, Sumi;
    • Lee, Moon‐kyu
    Publication type:
    Article
    38
    39
    40

    Efficacy and safety of gemigliptin, a dipeptidyl peptidase-4 inhibitor, in patients with type 2 diabetes mellitus inadequately controlled with combination treatment of metformin and sulphonylurea: a 24-week, multicentre, randomized, double-blind, placebo-controlled study ( TROICA study)

    Published in:
    Diabetes, Obesity & Metabolism, 2017, v. 19, n. 5, p. 635, doi. 10.1111/dom.12866
    By:
    • Ahn, Chang Ho;
    • Han, Kyung Ah;
    • Yu, Jae Myung;
    • Nam, Joo Young;
    • Ahn, Kyu Jeung;
    • Oh, Tae Keun;
    • Lee, Hyoung Woo;
    • Lee, Dae Ho;
    • Kim, Jaetaek;
    • Chung, Choon Hee;
    • Park, Tae Sun;
    • Kim, Byung Joon;
    • Park, Seok Won;
    • Park, Hyeong Kyu;
    • Lee, Kwang Jae;
    • Kim, Sang‐Wook;
    • Park, Jeong Hyun;
    • Ko, Kwan Pyo;
    • Kim, Chong Hwa;
    • Lee, Hyunjin
    Publication type:
    Article
    41

    Efficacy and safety of initial combination therapy with gemigliptin and metformin compared with monotherapy with either drug in patients with type 2 diabetes: A double-blind randomized controlled trial ( INICOM study).

    Published in:
    Diabetes, Obesity & Metabolism, 2017, v. 19, n. 1, p. 87, doi. 10.1111/dom.12787
    By:
    • Lim, Soo;
    • Han, Kyung Ah;
    • Yu, JaeMyung;
    • Chamnan, Parinya;
    • Kim, Eun Sook;
    • Yoon, Kun‐Ho;
    • Kwon, Sam;
    • Moon, Min Kyong;
    • Lee, Kwan Woo;
    • Kim, Dong‐Jun;
    • Kim, Mikyung;
    • Wongtanate, Manaj;
    • Kim, Eun Young;
    • Kim, Sung‐Ho;
    • Lee, Moon‐Kyu
    Publication type:
    Article
    42

    SLITRK2 variants associated with neurodevelopmental disorders impair excitatory synaptic function and cognition in mice.

    Published in:
    Nature Communications, 2022, v. 13, n. 1, p. 1, doi. 10.1038/s41467-022-31566-z
    By:
    • El Chehadeh, Salima;
    • Han, Kyung Ah;
    • Kim, Dongwook;
    • Jang, Gyubin;
    • Bakhtiari, Somayeh;
    • Lim, Dongseok;
    • Kim, Hee Young;
    • Kim, Jinhu;
    • Kim, Hyeonho;
    • Wynn, Julia;
    • Chung, Wendy K.;
    • Vitiello, Giuseppina;
    • Cutcutache, Ioana;
    • Page, Matthew;
    • Gecz, Jozef;
    • Harper, Kelly;
    • Han, Ah-reum;
    • Kim, Ho Min;
    • Wessels, Marja;
    • Bayat, Allan
    Publication type:
    Article
    43
    44
    45
    46
    47
    48
    49
    50